Jazz Pharmaceuticals (JAZZ) Change in Receivables (2010 - 2026)

Jazz Pharmaceuticals' Change in Receivables history runs 17 years deep, the most recent figure standing at $6.5 million for Q1 2026.

• In Q1 2026, Change in Receivables rose 109.85% year-over-year to $6.5 million; the TTM figure through Mar 2026 stood at $178.8 million (up 435.24% YoY), while the FY2025 annual figure was $106.3 million, up 403.33% from the prior year.
• Change in Receivables for Q1 2026 stood at $6.5 million, down from $65.8 million in the prior quarter.
• The five-year high for Change in Receivables was $75.5 million in Q4 2023, with the low at -$66.0 million in Q1 2025.
• The 5-year median for Change in Receivables is $9.7 million (2022), against an average of $16.2 million.
• Peak annual rise in Change in Receivables reached 7717.25% in 2025, while the deepest fall reached 881.71% in 2025.
• Jazz Pharmaceuticals' Change in Receivables stood at $46.3 million in 2022, then surged by 63.11% to $75.5 million in 2023, then tumbled by 101.14% to -$864000.0 in 2024, then jumped by 7717.25% to $65.8 million in 2025, then slumped by 90.12% to $6.5 million in 2026.
• Business Quant data shows JAZZ's Change in Receivables at $6.5 million in Q1 2026, $65.8 million in Q4 2025, and $51.0 million in Q3 2025.